title: [S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET].
abstract: OBJECTIVE
  Analyze the significance of serum S100 as tumor marker and study it in the sentinel node biopsy and in the whole body FDG-PET studies.
  
  
  METHODS
  332 melanoma patients diagnosed of cutaneous melanoma were included (41 untreated and 291 previously treated). Serum levels were measured by an immunoradiometric assay. Cut-off value was 0.2 microg/l.
  
  
  RESULTS
  In the 41 untreated patients, the S100 mean values were: mean 0.36 microg/l, median 0.29 microg/l, with 56.1% of positivities. Serum mean values in stage III and IV were significantly higher than stage I and II (0.489 microg/l vs 0.209 microg/l) (p < 0.05). The mean serum value of S100 in treated patients and without evidence of disease was 0.14 microg/l and the median 0.13 microg/l. Sensitivity and specificity for detection of recurrence or metastases in the follow-up were 76.2% and 88.6%, respectively. There is a correlation of 91.3% between S100 and FDG-PET studies (23 patients). S100 does not provide information on the sentinel lymph node biopsy.
  
  
  CONCLUSIONS
  S100 is not useful to diagnose melanoma in its early stages but it is a good tumor marker for the follow-up and monitoring of melanoma patients.
authors.affiliation: Sección de Marcadores Tumorales, Servicio de Laboratorio, Instituto Valenciano de Oncología, Valencia.
authors.forename: B
authors.initials: B
authors.lastname: Ortiz
authors.forename: C
authors.initials: C
authors.lastname: Vázquez
authors.forename: C
authors.initials: C
authors.lastname: Martínez
authors.forename: J
authors.initials: J
authors.lastname: Giménez
authors.forename: O
authors.initials: O
authors.lastname: Sanmartín
authors.forename: V
authors.initials: V
authors.lastname: de los Dolores
authors.forename: F
authors.initials: F
authors.lastname: Ortega
authors.forename: J
authors.initials: J
authors.lastname: Maíquez
authors.forename: M V
authors.initials: MV
authors.lastname: Fliquete
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008545:Melanoma / Q000097:blood / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000556:secondary; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D009418:S100 Proteins / Q000097:blood*; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000473:pathology*; D014055:Tomography, Emission-Computed
chemical_list: D014408:Biomarkers, Tumor; D009418:S100 Proteins; D019788:Fluorodeoxyglucose F18